Clinical Trial Update: CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study of CAMELLIA, an anti-CD47 antibody therapy, in hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CAMELLIA anti-CD47 antibody therapy (anti-CD47 antibody)

Snippet

Sponsor: Gilead Sciences | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED